Steven Cohen Viridian Therapeutics, Inc.\De Transaction History

Point72 Asset Management, L.P.

$36.6 Billion
Q3 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 34,627 shares of VRDN stock, worth $685,268. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,627

Holding current value

$685,268

% of portfolio

0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$12.16 - $23.33 $421,064 - $807,847	34,627 New	34,627 $787,000
Q3 2023 Nov 14, 2023	BUY	$15.16 - $24.7 $6.66 Million - $10.8 Million	439,191 New	439,191 $6.74 Million
Q1 2023 May 15, 2023	SELL	$25.04 - $37.6 $5.08 Million - $7.63 Million	-202,991 Reduced 78.05%	57,100 $1.45 Million
Q4 2022 Feb 14, 2023	SELL	$18.78 - $29.74 $499,848 - $791,559	-26,616 Reduced 9.28%	260,091 $7.6 Million
Q3 2022 Nov 14, 2022	SELL	$10.7 - $25.5 $5.39 Million - $12.8 Million	-503,693 Reduced 63.73%	286,707 $5.88 Million
Q2 2022 Aug 15, 2022	BUY	$9.55 - $19.0 $4.68 Million - $9.32 Million	490,400 Added 163.47%	790,400 $9.15 Million
Q1 2022 May 16, 2022	SELL	$16.79 - $20.88 $2.9 Million - $3.61 Million	-172,864 Reduced 36.56%	300,000 $5.55 Million
Q4 2021 Feb 14, 2022	SELL	$15.65 - $21.5 $2.15 Million - $2.95 Million	-137,136 Reduced 22.48%	472,864 $9.35 Million
Q3 2021 Nov 15, 2021	BUY	$10.69 - $18.2 $2.29 Million - $3.9 Million	214,466 Added 54.22%	610,000 $10 Million
Q1 2021 May 17, 2021	BUY	$15.5 - $24.93 $6.13 Million - $9.86 Million	395,534 New	395,534 $6.61 Million

Others Institutions Holding VRDN

# of Institutions

179

Shares Held

76.8M

Call Options Held

581K

Put Options Held

439K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $789M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account